Clinical application of circulating tumor cells detection

doi:10.3760/cma.j.issn.1673-422X.2014.02.007

Abstract

Abstract: irculating tumor cell (CTC) count is widely recognized in determining tumor stage, assessing prognosis, monitoring therapy response. But a lot of researches and clinical experiments are needed to establish a standardized evaluation system. Molecular detection of CTC not only can improve the CTC count, but also have immense potential for the auxiliary diagnosis and individual treatment of tumors and significance for understanding the biological behavior of tumor metastasis. It will become the hot spot of future research.

Key words: Circulating neoplasm cells, Neoplasm staging, Diagnosis, Prognosis, Treatment outcome

Li Pang, Gao Jie, Li Sheng. Clinical application of circulating tumor cells detection[J]. Journal of International Oncology, 2014, 41(2): 99-102.

References

［1］ Ilina O, Friedl P. Mechanisms of collective cell migration at a glance［J］. J Cell Sci, 2009, 122(Pt 18): 3203-3208. ［2］ Hou JM, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with smallcell lung cancer［J］. J Clin Oncol, 2012, 30(5): 525-532. ［3］ Sun YF, Xu Y, Yang XR, et al. Circulating stem celllike epithelial cell adhesion moleculepositive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection［J］. Hepatology, 2013, 57(4): 14581468. ［4］ Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer［J］. Clin Cancer Res, 2009, 15(22): 6980-6986. ［5］ Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with nonsmallcell lung cancer［J］. J Clin Oncol, 2011, 29(12): 1556-1563. ［6］ Msaouel P, Koutsilieris M. Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and metaanalysis［J］. BMC Cancer, 2011, 11: 336. ［7］ Resel Folkersma L, San José Manso L, Galante Romo I, et al. Prognostic significance of circulating tumor cell count in patients with metastatic hormonesensitive prostate cancer［J］. Urology, 2012, 80(6): 1328-1332. ［8］ Khan MS, Kirkwood A, Tsigani T, et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors［J］. J Clin Oncol, 2013, 31(3): 365-372. ［9］ Blke E, Orth K, Gerber PA, et al. Gene expression of circulating tumour cells and its correlation with tumour stage in breast cancer patients［J］. Eur J Med Res, 2009, 14(8): 359-363. ［10］ Rink M, Chun FK, Dahlem R, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study［J］. Eur Urol, 2012, 61(4): 810-817. ［11］ Hayashi N, Nakamura S, Tokuda Y, et al. Prognostic value of HER2positive circulating tumor cells in patients with metastatic breast cancer［J］. Int J Clin Oncol, 2012, 17(2): 96-104. ［12］ Pailler E, Adam J, Barthélémy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALKpositive nonsmallcell lung cancer［J］. J Clin Oncol, 2013, 31(18): 2273-2281. ［13］ Khoja L, Lorigan P, Zhou C, et al. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma［J］. J Invest Dermatol, 2013, 133(6): 1582-1590. ［14］ Naito T, Tanaka F, Ono A, et al. Prognostic impact of circulating tumor cells in patients with small cell lung cancer［J］. J Thorac Oncol, 2012, 7(3): 512-519. ［15］ Matsusaka S, Chin K, Ogura M, et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer［J］. Cancer Sci, 2010, 101(4): 1067-1071. ［16］ Iinuma H, Watanabe T, Mimori K, et al. Clinical significance of circulating tumor cells, including cancer stemlike cells, in peripheral blood for recurrence and prognosis in patients with Dukes′ stage B and C colorectal cancer［J］. J Clin Oncol, 2011, 29(12): 1547-1555. ［17］ Yokobori T, Iinuma H, Shimamura T, et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelialmesenchymal transition and is associated with colorectal cancer prognosis［J］. Cancer Res, 2013, 73(7): 2059-2069. ［18］ Nolé F, Munzone E, Zorzino L, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications［J］. Ann Oncol, 2008, 19(5): 891-897. ［19］ Hartkopf AD, Wagner P, Wallwiener D, et al. Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer［J］. Anticancer Res, 2011, 31(3): 979-984. ［20］ Lu CY, Tsai HL, Uen YH, et al. Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage Ⅲ colon cancer［J］. Br J Cancer, 2013, 108(4): 791-797. ［21］ Jatana KR, Balasubramanian P, Lang JC, et al. Significance of circulating tumor cells in patients with squamous cell carcinoma of the head and neck: initial results［J］. Arch Otolaryngol Head Neck Surg, 2010, 136(12): 1274-1279. ［22］ Contractor K, Aboagye EO, Jacob J, et al. Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and ［(18)F］ 3′ deoxy3′fluorothymidine PET: a pilot study［J］. Biomark Med, 2012, 6(2): 231-233. ［23］ Pachmann K, Camara O, Kroll T, et al. Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neupositive breast carcinoma［J］. J Cancer Res Clin Oncol, 2011, 137(9): 1317-1327. ［24］ Yin XD, Yuan X, Xue JJ, et al. Clinical significance of carcinoembryonic antigen, cytokeratin 19, or survivinpositive circulating tumor cells in the peripheral blood of esophageal squamous cell carcinoma patients treated with radiotherapy［J］. Dis Esophagus, 2012, 25(8): 750-756. ［25］ Somlo G, Lau SK, Frankel P, et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage Ⅳ breast cancer, using a novel detection technology［J］. Breast Cancer Res Treat, 2011, 128(1): 155-163. ［26］ Sakaizawa K, Goto Y, Kiniwa Y, et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level［J］. Br J Cancer, 2012, 106(5): 939-946. ［27］ Chen CL, Mahalingam D, Osmulski P, et al. Singlecell analysis of circulating tumor cells identifies cumulative expression patterns of EMTrelated genes in metastatic prostate cancer［J］. Prostate, 2013, 73(8): 813-826.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[6]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[7]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[8]	Chen Qi, Xu Chenyang, Wang Yin, Lei Dapeng. Current application status of hyperspectral imaging in the diagnosis and treatment of head and neck tumor [J]. Journal of International Oncology, 2024, 51(5): 298-302.
[9]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[10]	Wang Kun, Zhou Zhongxin, Zang Qiwei. Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection [J]. Journal of International Oncology, 2024, 51(4): 198-203.
[11]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[12]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[13]	Yan Aiting, Wang Cuizhu, Liu Chungui, Lu Xiaomin. Clinical efficacy and safety of camrelizumab and sintilimab in the treatment of advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 137-142.
[14]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[15]	Zhang Lili, Tan Ru, Fang Xueli, Yang Yu, Sang Zheng, Li Baosheng. Imaging diagnosis， pathological upgrade， and imaging technology progress of ductal carcinoma in situ of the breast [J]. Journal of International Oncology, 2024, 51(3): 166-169.